Literature DB >> 19657708

Rheumatoid arthritis associated with osteopetrosis.

Yuho Kadono1, Sakae Tanaka, Jinju Nishino, Keita Nishimura, Ichiro Nakamura, Tsuyoshi Miyazaki, Hiroshi Takayanagi, Kozo Nakamura.   

Abstract

Osteopetrosis is an inherited disorder characterized by reduced bone resorption. We here report a rare case of osteopetrosis associated with rheumatoid arthritis. The patient was diagnosed as autosomal dominant osteopetrosis type II in his youth and developed rheumatoid arthritis at 42 years of age. In spite of the severe inflammation and rapid progression of cartilage destruction, the progression of bone erosion was slow in this patient.

Entities:  

Mesh:

Year:  2009        PMID: 19657708     DOI: 10.1007/s10165-009-0208-7

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

1.  Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.

Authors:  Mizuho Kittaka; Kotoe Mayahara; Tomoyuki Mukai; Tetsuya Yoshimoto; Teruhito Yoshitaka; Jeffrey P Gorski; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2017-11-02       Impact factor: 6.741

Review 2.  RANKL as a therapeutic target of rheumatoid arthritis.

Authors:  Sakae Tanaka; Yoshiya Tanaka
Journal:  J Bone Miner Metab       Date:  2020-10-18       Impact factor: 2.626

Review 3.  Immune-bone interplay in the structural damage in rheumatoid arthritis.

Authors:  N Komatsu; H Takayanagi
Journal:  Clin Exp Immunol       Date:  2018-09-04       Impact factor: 4.330

4.  Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways.

Authors:  Sakae Tanaka
Journal:  World J Orthop       Date:  2013-01-18

Review 5.  Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.

Authors:  Morten A Karsdal; Thasia Woodworth; Kim Henriksen; Walter P Maksymowych; Harry Genant; Philippe Vergnaud; Claus Christiansen; Tanja Schubert; Per Qvist; Georg Schett; Adam Platt; Anne-Christine Bay-Jensen
Journal:  Arthritis Res Ther       Date:  2011-04-28       Impact factor: 5.156

Review 6.  RANKL is a therapeutic target of bone destruction in rheumatoid arthritis.

Authors:  Sakae Tanaka
Journal:  F1000Res       Date:  2019-04-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.